US reclassifies cannabis as Schedule III, exposing racial disparities in drug policy and corporate capture of reform
Original framing: “US reclassifies certain marijuana products as a less-dangerous drug - Reuters” — Reuters (via Google News)
Scientific consensus supports the reclassification of cannabis as less harmful than Schedule I substances, given its lower potential for addiction and overdose compared to opioids or stimulants. Studies show that Schedule III classification aligns with evidence that cannabis has medical benefits, particularly for chronic pain, epilepsy, and nausea. However, the DEA's decision is also influenced by pharmaceutical industry lobbying, which seeks to monopolize cannabis-based medicines. The lack of comprehensive clinical trials on cannabis is partly due to its Schedule I status, which has historically restricted research funding and access to samples.
The US reclassification of cannabis as Schedule III is a symptom of a broader systemic shift where drug policy reform is increasingly shaped by corporate lobbying and racial justice narratives, rather than public health or social equity.
This move reflects the legacy of the 1970 Controlled Substances Act, which was designed to criminalize Black and Latino communities while suppressing hemp competition, yet mainstream coverage frames it as a bipartisan achievement. The failure to address racial disparities in enforcement, lack of expungement for past convictions, and corporate capture of the cannabis market reveals how reform can be co-opted to serve elite interests. Globally, this policy contrasts with harm reduction models in Portugal and Indigenous knowledge systems that have long recognized cannabis as a medicinal and spiritual plant, yet these perspectives are systematically excluded from policy discussions. The solution lies in decriminalization paired with social equity mandates, Indigenous knowledge integration, corporate accountability, and global harm reduction advocacy—measures that would address the root causes of inequity while fostering a more just and sustainable cannabis economy.